<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-22T07:57:45Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/107CBDDF-CE25-4FAC-91C6-6104BE9D0E92" ns1:id="107CBDDF-CE25-4FAC-91C6-6104BE9D0E92"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/BBA0C8D8-07A1-4012-9269-2C98E690FE91" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/81D47294-9506-4BE8-BAC2-7652DE47C801" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/81D47294-9506-4BE8-BAC2-7652DE47C801" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/99C95C72-445E-43B2-8099-A8100052D07F" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2018-09-29T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/E966D39B-7859-4A04-803D-E17219D6B7D5" ns1:rel="FUND" ns1:start="2017-09-30T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">133103</ns2:identifier></ns2:identifiers><ns2:title>Development of a rapid, point of care screening test for Staphylococcus aureus for acute patient admissions</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Modified Screening Guidance provided to the NHS removes the mandatory element of screening for MRSA. Commentary on the proposal from 4 hospital infection control groups suggest change away from universal screening can be expected to lead to a greater number of undetected MRSA patients, with a potentially greater transmission risk. This project develops Kingston University’s patent-pending fluorescence probe (LGX) that can detect SA at low bacterial concentration within 30 minutes, without the need for microbiological culturing and at a reduced cost. It will develop the technology from a bench test to a prototype assay validated by means of a clinical/usability study.</ns2:abstractText></ns2:project>